Stephen V Liu

35PUBLICATIONS
272CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAutonomic nervous systemPredictive and prognostic markersNeurosciences not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Apr 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.

Jhanelle E Gray, Joel W Neal, Jyoti D Patel

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Dec 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions.

Tejas Patil, Jessica J Lin, Parneet K Cheema

|Dec 10, 2025
Expanding targeted therapy for lung cancer.

Wenners Ballard, Muskan Agarwal, Stephen V Liu

|Oct 17, 2025
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.

Stephen V Liu, Riddhi A Babel, Yu-Han Kao

Pageof 6

Frequent Collaborators

7 joint publications

Chul Kim

5 joint publications

Alexander Drilon

4 joint publications

Misako Nagasaka

3 joint publications

Ticiana Leal